
Talking Clinical Trials: Participant's experience and perspective
10/07/21 • 23 min
Join Colm, Professor Steve Macfarlane, Maree Mastwyk, Trish and John as they discuss the personal and professional characteristics of a clinical trial.
Professor Steve Macfarlane is the Head of Clinical Services at HammondCare's Dementia Centre and his colleague, Maree Mastwyk is a Team leader of Clinical trials. Together they define clinical trials in a professional context and provide their expertise on how to operate a clinical trial.
John, a person living with dementia and his partner Trish are both currently on a clinical trial. They describe their personal experiences of this trial.
The Australian Clinical Trials Alliance’s ‘Report on the Activities & Achievements of Clinical Trials Networks in Australia’ and an article by the Western Alliance are informative resources on the operations of clinical trials in Australia.
Policy & Medicine’s article 'The Importance of Clinical Trials' explains the impact of clinical trials in America.
ANZCTR is an online registry for of clinical trials being undertaken predominately in Australia and New Zealand, and to a smaller extent other parts of the globe. This link connects you to a similar network in the America and here is a dementia research registry located in the United Kingdom.
*We would like to acknowledge as clinical best practise is continuously evolving that the comments made in this episode is reflective of the period leading up to the 7th of October.
Below we have listed the definitions of some terms mentioned in this episode:
Efficacious: Something is able to produce its intended result.
Placebo: A substance given to someone who is told that it is a particular medicine, either to make that person feel as if they are getting better or to compare the effect of the particular medicine when given to others.
Sponsor: Any individual or group that provides financial or material support to a study or endeavour in return for commercial advertisement.
Comparator: The comparator study is used to compare the effectiveness of the investigational product to the existing drug.
Tolerability: Represents the degree to which overt adverse effects can be tolerated by the subject/patient.
Con-meds: Concomitant medications (con-meds) are any prescription or over-the-counter drugs and supplements taken in addition to an investigational therapy by a study subject.
Proof of concept: Proof of concept (POC) is an exercise in which work is focused on determining whether an idea can be turned into a reality. A proof of concept is meant to determine the feasibility of the idea or to verify that the idea will function as envisioned. It is sometimes also known as proof of principle.
Adverse events: An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse events may be mild, moderate, or severe, and may be caused by something other than the drug or therapy being given. Also called adverse effect.
For all feedback please email [email protected]
Join Colm, Professor Steve Macfarlane, Maree Mastwyk, Trish and John as they discuss the personal and professional characteristics of a clinical trial.
Professor Steve Macfarlane is the Head of Clinical Services at HammondCare's Dementia Centre and his colleague, Maree Mastwyk is a Team leader of Clinical trials. Together they define clinical trials in a professional context and provide their expertise on how to operate a clinical trial.
John, a person living with dementia and his partner Trish are both currently on a clinical trial. They describe their personal experiences of this trial.
The Australian Clinical Trials Alliance’s ‘Report on the Activities & Achievements of Clinical Trials Networks in Australia’ and an article by the Western Alliance are informative resources on the operations of clinical trials in Australia.
Policy & Medicine’s article 'The Importance of Clinical Trials' explains the impact of clinical trials in America.
ANZCTR is an online registry for of clinical trials being undertaken predominately in Australia and New Zealand, and to a smaller extent other parts of the globe. This link connects you to a similar network in the America and here is a dementia research registry located in the United Kingdom.
*We would like to acknowledge as clinical best practise is continuously evolving that the comments made in this episode is reflective of the period leading up to the 7th of October.
Below we have listed the definitions of some terms mentioned in this episode:
Efficacious: Something is able to produce its intended result.
Placebo: A substance given to someone who is told that it is a particular medicine, either to make that person feel as if they are getting better or to compare the effect of the particular medicine when given to others.
Sponsor: Any individual or group that provides financial or material support to a study or endeavour in return for commercial advertisement.
Comparator: The comparator study is used to compare the effectiveness of the investigational product to the existing drug.
Tolerability: Represents the degree to which overt adverse effects can be tolerated by the subject/patient.
Con-meds: Concomitant medications (con-meds) are any prescription or over-the-counter drugs and supplements taken in addition to an investigational therapy by a study subject.
Proof of concept: Proof of concept (POC) is an exercise in which work is focused on determining whether an idea can be turned into a reality. A proof of concept is meant to determine the feasibility of the idea or to verify that the idea will function as envisioned. It is sometimes also known as proof of principle.
Adverse events: An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse events may be mild, moderate, or severe, and may be caused by something other than the drug or therapy being given. Also called adverse effect.
For all feedback please email [email protected]
Previous Episode

Talking Topaz: An international knowledge exchange
Join Colm in a unique ‘live’ episode to celebrate World Alzheimer’s Day and Dementia Action Week.
This episode allows us to join part of the discussion on the 'Stronger Together' webinar that launched HammondCare and it’s Dementia Centre ‘s partnership with Topaz , a leading Dutch aged care provider.
This conversation centres around the importance of international partnership and knowledge exchange to raise awareness and increase learnings in the field of dementia care and research.
Colm gets out of the host seat and joins the panel, as we join our host Marie Alford, Head of Dementia Services at the Dementia Centre. Marie is joined by Topaz CEO Lia de Jongh, Professor Wilco Achterberg, Leiden University Professor of Institutional Care and Elderly Care Medicine and Professor Susan Kurrle, University of Sydney Curran Chair of Health in Older People.
Don’t forget to click on the full webinar link in the show notes to hear, as the Dutch General Counsel to Australia, Frank van Beuningen and Australian Ambassador to the Netherlands, Matthew Neuhaus help launch this new initiative.
The research paper 'Clustered domestic residential aged care in Australia: fewer hospitalisations and better quality of life' is an example of the work that HammondCare’s Dementia Centre will be sharing with Topaz in their knowledge exhange partnership.
Here are some examples of the work that Professor Wilco Achterberg has completed and Topaz will share with HammondCare’s Dementia Centre in return.
For all feedback please email [email protected]
Next Episode

Talking Dementia: Reminiscence and Life Story Work
Join Colm, Professor Assumpta Ryan and Professor Faith Gibson in their discussion of the meaning and best practice implementation of reminiscence and life story work in dementia care.
Professor Faith Gibson is a friend and colleague of Colm, who has informed much of the work of HammondCare's Dementia Centre . A social worker by training, Faith is a pioneer in the field of reminiscence and life story work. Her most recent publication 'International Perspectives on Reminiscence, Life Review and Life Story Work' and earlier work 'Reminiscence and Life Story Work. A Practice Guide' are informative and instructional resources on reminiscence work.
Together, Colm, Faith and Assumpta provide insight, guidance and shared experience to this episode.
The Cochrane Library’s 1998, 2005 and current 2018 review 'Reminiscence therapy for dementia' displays over time, how memories and past experiences with other people using tangible prompts evokes memories and stimulate conversation for those living with dementia.
'International Journey of Reminiscence and Life Review' publishes original work exploring the nature, function, and application of remembering the personal past within a wide range of research contexts and practice settings..
The European Reminiscence Network and American International Center for Life Story Innovations and Practise promote best practice in reminiscence work and to share experience across national frontiers.
The Dementia Podcast - Talking Clinical Trials: Participant's experience and perspective
Transcript
Hello to you, and welcome back to the Dementia Podcast. As always, I'm your host, Colm Cunningham, and it's great to have you with us. In this episode, we're going to be talking to people who've participated in clinical trials for treatment related to their symptoms of dementia. With my guest today, we'll be exploring not only the clinical, but the personal and practical elements of these trials, sharing their experiences along the way. So why are we
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/the-dementia-podcast-231559/talking-clinical-trials-participants-experience-and-perspective-26068404"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to talking clinical trials: participant's experience and perspective on goodpods" style="width: 225px" /> </a>
Copy